创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

HAN Jia, ZHENG Xiaonan. Comparative Analysis of the Industry Status & Trend between Biosimilars and Biobetters[J]. Progress in Pharmaceutical Sciences, 2018, 42(6): 439-449.
Citation: HAN Jia, ZHENG Xiaonan. Comparative Analysis of the Industry Status & Trend between Biosimilars and Biobetters[J]. Progress in Pharmaceutical Sciences, 2018, 42(6): 439-449.

Comparative Analysis of the Industry Status & Trend between Biosimilars and Biobetters

  • With the increasing maturity of regulatory law & policies and the gradual acceptance of biosimilars and biobetters by stakeholders, a clear and comprehensive understanding about the industry status & trend of biosimilars and biobetters is beneficial for biopharmaceutical companies to map out reasonable development strategy for investment and cooperation and thus promote their R&D of biologics and participation in the competition in regional or global market. In order to provide relevant organizations with effective decision-making support based on competitive intelligence for the strategy formulation and implementation of R&D, investment and cooperation in biopharmaceutical industry, this paper firstly made a clear definition and introduction of biosimilars and biobetters, then comparatively analyzed the industry status & trend of biosimilars and biobetters from the perspectives of R&D progress, competitive landscape, advantages & disadvantages, and risk & value in major countries or regional markets.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return